Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dactinomycin

FDA-approved product (injectable, injection), marketed as Cosmegen, Dactinomycin.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Dactinomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Kidney Wilms tumor
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Actinomycines
FDA pharmacologic class
Actinomycin FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA95.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
Open Dactinomycin in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dactinomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6

    NCT03885388 · start 2019-03-08

    Registered record
    Registry ID
    NCT03885388
    Conditions
    Gestational Trophoblastic Tumor; Effects of Chemotherapy; Drug Toxicity
    Interventions
    MTX; MTX+ACTD
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-03-08
    Completion
    2023-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Trophoblastic Tumor; Effects of Chemotherapy; Drug Toxicity
    InterventionMTX; MTX+ACTD
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • International PPB/DICER1 Registry

    NCT03382158 · start 2016-12-06

    Registered record
    Registry ID
    NCT03382158
    Conditions
    Pleuropulmonary Blastoma; Sertoli-Leydig Cell Tumor; DICER1 Syndrome; Cystic Nephroma; Wilms Tumor; Pineoblastoma; Renal Sarcoma; Nodular Hyperplasia of Thyroid; Nasal Chondromesenchymal Hamartoma; Ciliary Body Medulloepithelioma; Neuroblastoma; Pituitary Cancer; Embryonal Rhabdomyosarcoma; Ovarian Sarcoma; Gynandroblastoma; Thyroid Carcinoma; Embryonal Rhabdomyosarcoma of Vagina (Diagnosis); Embryonal Rhabdomyosarcoma of Uterus (Diagnosis); Embryonal Rhabdomyosarcoma of Cervix
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2016-12-06
    Completion
    2035-12-06
    Enrolment
    3,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPleuropulmonary Blastoma; Sertoli-Leydig Cell Tumor; DICER1 Syndrome; Cystic Nephroma +15 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

    NCT02639650 · start 2016-03-01

    Registered record
    Registry ID
    NCT02639650
    Conditions
    Gestational Trophoblastic Neoplasms
    Interventions
    Etoposide; actinomycin D; methotrexate; vincristine; cyclophosphamide; Paclitaxel; Cisplatin; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-03-01
    Completion
    2026-03-01
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Trophoblastic Neoplasms
    InterventionEtoposide; actinomycin D; methotrexate; vincristine +4 more
    PhasePhase 3
    Registry statusUnknown

  • Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

    NCT01531244 · start 2014-12

    Registered record
    Registry ID
    NCT01531244
    Conditions
    Melanoma
    Interventions
    dactinomycin; melphalan; Conditionally replicative adenovirus 3/5-delta
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2014-12
    Completion
    2016-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    Interventiondactinomycin; melphalan; Conditionally replicative adenovirus 3/5-delta
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia

    NCT01823315 · start 2012-12

    Registered record
    Registry ID
    NCT01823315
    Conditions
    Gestational Trophoblastic Disease; Gestational Trophoblastic Neoplasia; Gestational Trophoblastic Tumor; Gestational Trophoblastic Neoplasms
    Interventions
    MTX 1; MTX 2; Act-d
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2012-12
    Completion
    2019-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGestational Trophoblastic Disease; Gestational Trophoblastic Neoplasia; Gestational Trophoblastic Tumor; Gestational Trophoblastic Neoplasms
    InterventionMTX 1; MTX 2; Act-d
    PhasePhase 3
    Registry statusUnknown

  • Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

    NCT01323517 · start 2011-02

    Registered record
    Registry ID
    NCT01323517
    Conditions
    Melanoma
    Interventions
    Ipilimumab, Melphalan and Dactinomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-02
    Completion
    2017-08-14
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionIpilimumab, Melphalan and Dactinomycin
    PhasePhase 2
    Registry statusCompleted

  • Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

    NCT01055314 · start 2010-01

    Registered record
    Registry ID
    NCT01055314
    Conditions
    Adult Rhabdomyosarcoma; Childhood Alveolar Rhabdomyosarcoma; Childhood Embryonal Rhabdomyosarcoma; Metastatic Childhood Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma; Untreated Childhood Rhabdomyosarcoma
    Interventions
    Cixutumumab; Cyclophosphamide; Dactinomycin; Doxorubicin Hydrochloride; Etoposide; Ifosfamide; Irinotecan Hydrochloride; Laboratory Biomarker Analysis; Temozolomide; Vincristine Sulfate Liposome
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-01
    Completion
    2016-06
    Enrolment
    175

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Rhabdomyosarcoma; Childhood Alveolar Rhabdomyosarcoma; Childhood Embryonal Rhabdomyosarcoma; Metastatic Childhood Soft Tissue Sarcoma +2 more
    InterventionCixutumumab; Cyclophosphamide; Dactinomycin; Doxorubicin Hydrochloride +6 more
    PhasePhase 2
    Registry statusCompleted

  • International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

    NCT01464606 · start 2009-12-22

    Registered record
    Registry ID
    NCT01464606
    Conditions
    Pleuropulmonary Blastoma
    Interventions
    Vincristine; Dactinomycin; Cyclophosphamide; Ifosfamide; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2009-12-22
    Completion
    2028-12
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPleuropulmonary Blastoma
    InterventionVincristine; Dactinomycin; Cyclophosphamide; Ifosfamide +1 more
    PhaseNot applicable
    Registry statusActive not recruiting

  • Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

    NCT01014767 · start 2009-11

    Registered record
    Registry ID
    NCT01014767
    Conditions
    Brain Cancer; Choroid Plexus Tumors
    Interventions
    Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Irinotecan; Leucovorin; Methotrexate; Temozolomide; Vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2009-11
    Completion
    2014-01
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Cancer; Choroid Plexus Tumors
    InterventionCarboplatin; Cisplatin; Cyclophosphamide; Dactinomycin +7 more
    PhasePhase 3
    Registry statusTerminated

  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

    NCT00945009 · start 2009-08-24

    Registered record
    Registry ID
    NCT00945009
    Conditions
    Adult Kidney Wilms Tumor; Beckwith-Wiedemann Syndrome; Childhood Kidney Wilms Tumor; Diffuse Hyperplastic Perilobar Nephroblastomatosis; Rhabdoid Tumor of the Kidney; Stage I Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor; Stage V Kidney Wilms Tumor
    Interventions
    Dactinomycin; Doxorubicin Hydrochloride; Radiation Therapy; Therapeutic Conventional Surgery; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-08-24
    Completion
    2026-03-31
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Kidney Wilms Tumor; Beckwith-Wiedemann Syndrome; Childhood Kidney Wilms Tumor; Diffuse Hyperplastic Perilobar Nephroblastomatosis +6 more
    InterventionDactinomycin; Doxorubicin Hydrochloride; Radiation Therapy; Therapeutic Conventional Surgery +1 more
    PhasePhase 3
    Registry statusCompleted

  • Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

    NCT00940524 · start 2009-07

    Registered record
    Registry ID
    NCT00940524
    Conditions
    Leukemia; Acute Lymphoblastic Leukemia
    Interventions
    Dasatinib, Mitoxantrone, Cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-07
    Completion
    2014-04
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Acute Lymphoblastic Leukemia
    InterventionDasatinib, Mitoxantrone, Cytarabine
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma

    NCT02063022 · start 2009-01-22

    Registered record
    Registry ID
    NCT02063022
    Conditions
    Ewing's Sarcoma
    Interventions
    Standard treatment (as per protocol ISG SSG III); Intensified chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-01-22
    Completion
    2022-04-14
    Enrolment
    278

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEwing's Sarcoma
    InterventionStandard treatment (as per protocol ISG SSG III); Intensified chemotherapy
    PhasePhase 3
    Registry statusCompleted

  • Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

    NCT00674193 · start 2008-02

    Registered record
    Registry ID
    NCT00674193
    Conditions
    Childhood Acute Lymphoblastic Leukemia; Childhood Rhabdomyosarcoma; Childhood Soft Tissue Sarcoma; Ewing Sarcoma; Ewing Sarcoma of Bone; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET); Unspecified Childhood Solid Tumor, Protocol Specific; Wilms Tumor and Other Childhood Kidney Tumors
    Interventions
    pharmacological study; laboratory biomarker analysis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-02
    Completion
    Not recorded
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Acute Lymphoblastic Leukemia; Childhood Rhabdomyosarcoma; Childhood Soft Tissue Sarcoma; Ewing Sarcoma +4 more
    Interventionpharmacological study; laboratory biomarker analysis
    PhaseNot recorded
    Registry statusCompleted

  • Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

    NCT00379340 · start 2007-04-30

    Registered record
    Registry ID
    NCT00379340
    Conditions
    Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor
    Interventions
    3-Dimensional Conformal Radiation Therapy; Conventional Surgery; Cyclophosphamide; Dactinomycin; Doxorubicin Hydrochloride; Etoposide; Vincristine Sulfate Liposome
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-04-30
    Completion
    2026-03-31
    Enrolment
    395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor
    Intervention3-Dimensional Conformal Radiation Therapy; Conventional Surgery; Cyclophosphamide; Dactinomycin +3 more
    PhasePhase 3
    Registry statusCompleted

  • Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

    NCT00352534 · start 2006-11-06

    Registered record
    Registry ID
    NCT00352534
    Conditions
    Stage I Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor
    Interventions
    3-Dimensional Conformal Radiation Therapy; Biospecimen Collection; Chest Radiography; Computed Tomography; Dactinomycin; Doxorubicin Hydrochloride; Echocardiography Test; Magnetic Resonance Imaging; Therapeutic Conventional Surgery; Ultrasound Imaging; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11-06
    Completion
    2026-03-31
    Enrolment
    808

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage I Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor
    Intervention3-Dimensional Conformal Radiation Therapy; Biospecimen Collection; Chest Radiography; Computed Tomography +7 more
    PhasePhase 3
    Registry statusCompleted